Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Stroke Patients

NCT ID: NCT05122637

Last Updated: 2023-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2022-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Feasibility Study to evaluate the initial safety and performance of the RapidPulseTM Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the initial safety and performance of the RapidPulse Inc. RapidPulseTM Aspiration System as frontline approach for use in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO). This is a prospective, multi-center, open label study comparing the safety and performance of the RapidPulseTM Aspiration System with non-randomized retrospective controls who otherwise meet the same study inclusion/exclusion criteria. The study will enroll a maximum of 100 participants in the Treatment Arm and a maximum of 200 participants in the Control Arm at in up to 10 centers in Europe and/or Latin America. Subjects data will be collected through hospitalization with a 3 months post-procedure study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.

Group Type EXPERIMENTAL

RapidPulseTM Aspiration System

Intervention Type DEVICE

The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.

Control Arm

Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.

Group Type OTHER

Standard of Care Aspiration Thrombectomy System

Intervention Type DEVICE

Commercially available aspiration catheter with commercially available aspiration pump

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RapidPulseTM Aspiration System

The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.

Intervention Type DEVICE

Standard of Care Aspiration Thrombectomy System

Commercially available aspiration catheter with commercially available aspiration pump

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older
* Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6 with symptom onset (or last seen normal) up to 24 hours
* Large vessel occlusion in the intracranial internal carotid artery (ICA), middle cerebral artery (MCA) M1 or M2 segments, basilar or vertebral artery

Exclusion Criteria

* Evidence of hemorrhage
* Significant mass effect and/or midline shift
* Vessel tortuosity too difficult to allow endovascular access per investigator judgment
* Severe or fatal co-morbidities
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RapidPulse, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raul G Nogueira, MD

Role: STUDY_CHAIR

University of Pittsburgh Medical Center Stroke Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

General Hospital of Fortaleza

Fortaleza, , Brazil

Site Status

Odense University Hospital

Odense, , Denmark

Site Status

Pauls Stradiņš Clinical University Hospital

Riga, , Latvia

Site Status

Hospital General Universitari d'Alicante

Alicante, , Spain

Site Status

Istanbul Aydin University

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil Denmark Latvia Spain Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DEV-0213

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.